These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 28045912)

  • 21. Raf kinase inhibitory protein role in the molecular subtyping of breast cancer.
    Al-Mulla F; Marafie M; Zea Tan T; Paul Thiery J
    J Cell Biochem; 2014 Mar; 115(3):488-97. PubMed ID: 24123286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Claudin expression in breast cancer: high or low, what to expect?
    Ricardo S; Gerhard R; Cameselle-Teijeiro JF; Schmitt F; Paredes J
    Histol Histopathol; 2012 Oct; 27(10):1283-95. PubMed ID: 22936447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
    Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
    Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
    Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
    Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
    Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
    JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue.
    Hein S; Müller V; Köhler N; Wikman H; Krenkel S; Streichert T; Schweizer M; Riethdorf S; Assmann V; Ihnen M; Beck K; Issa R; Jänicke F; Pantel K; Milde-Langosch K
    Breast Cancer Res Treat; 2011 Sep; 129(2):347-60. PubMed ID: 20972617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.
    Chen Y; Song J; Jiang Y; Yu C; Ma Z
    Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas.
    Gerhard R; Ricardo S; Albergaria A; Gomes M; Silva AR; Logullo ÂF; Cameselle-Teijeiro JF; Paredes J; Schmitt F
    Breast; 2012 Jun; 21(3):354-60. PubMed ID: 22464177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer.
    Bernardi MA; Logullo AF; Pasini FS; Nonogaki S; Blumke C; Soares FA; Brentani MM
    Oncol Rep; 2012 Jan; 27(1):28-38. PubMed ID: 21956537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
    Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
    Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rab25 acts as an oncogene in luminal B breast cancer and is causally associated with Snail driven EMT.
    Mitra S; Federico L; Zhao W; Dennison J; Sarkar TR; Zhang F; Takiar V; Cheng KW; Mani S; Lee JS; Mills GB
    Oncotarget; 2016 Jun; 7(26):40252-40265. PubMed ID: 27259233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breast-conserving therapy for triple-negative breast cancer.
    Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
    JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathologic relevance of claudin 5 expression in breast cancer.
    Sugimoto H; Nagahara M; Bae Y; Nakagawa T; Ishikawa T; Sato T; Uetake H; Eishi Y; Sugihara K
    Am J Clin Pathol; 2015 Apr; 143(4):540-6. PubMed ID: 25780006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers.
    Choi J; Jung WH; Koo JS
    Histol Histopathol; 2012 Nov; 27(11):1481-93. PubMed ID: 23018247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
    Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
    Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined Proteomics and Transcriptomics Identifies Carboxypeptidase B1 and Nuclear Factor κB (NF-κB) Associated Proteins as Putative Biomarkers of Metastasis in Low Grade Breast Cancer.
    Bouchal P; Dvořáková M; Roumeliotis T; Bortlíček Z; Ihnatová I; Procházková I; Ho JT; Maryáš J; Imrichová H; Budinská E; Vyzula R; Garbis SD; Vojtěšek B; Nenutil R
    Mol Cell Proteomics; 2015 Jul; 14(7):1814-30. PubMed ID: 25903579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Re-definition of claudin-low as a breast cancer phenotype.
    Fougner C; Bergholtz H; Norum JH; Sørlie T
    Nat Commun; 2020 Apr; 11(1):1787. PubMed ID: 32286297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
    Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
    Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
    Lips EH; Mulder L; de Ronde JJ; Mandjes IA; Vincent A; Vrancken Peeters MT; Nederlof PM; Wesseling J; Rodenhuis S
    Breast Cancer Res Treat; 2012 Feb; 131(3):827-36. PubMed ID: 21472434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients.
    Laurberg T; Alsner J; Tramm T; Jensen V; Lyngholm CD; Christiansen PM; Overgaard J
    Acta Oncol; 2017 Jan; 56(1):59-67. PubMed ID: 27846764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.